Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.742091
Title: A comparison of medication adherence and persistence across drug classes in people with type 2 diabetes
Author: Mcgovern, Andrew P.
ISNI:       0000 0004 7226 5091
Awarding Body: University of Surrey
Current Institution: University of Surrey
Date of Award: 2018
Availability of Full Text:
Access from EThOS:
Access from Institution:
Abstract:
Medication non-adherence and non-persistence in type 2 diabetes (T2D) are common and associated with poor outcomes. Medication attributes have a major influence on adherence in chronic disease but it is not clear which medication classes are associated with better adherence and persistence in T2D. A systematic review and cohort analyses of comparative adherence and persistence across medication classes in T2D was performed. MEDLINE, Embase, The Cochrane Library, The Cochrane Register of Controlled Trials, PsycINFO, and CINAHL were searched for studies comparing class adherence and persistence. Where n > 5 studies provided the same comparison a meta-analysis was performed. Retrospective cohort analyses used the Royal College of General Practitioners Research and Surveillance database to compare adherence and persistence with oral medications. The systematic review synthesised 66 studies (38 in meta-analyses). Adherence was better with thiazolidinediones (TZDs) and sulphonylureas than metformin. TZDs had slightly better adherence than sulphonylureas. Limited data suggest low adherence with alpha-glucosidase inhibitors (AGIs) and meglitinides. Insulin analogues had longer persistence than GLP1 analogues and human insulins. There was little data on comparative persistence with oral medications and adherence with injectable medications. Adherence and persistence were measured in cohorts of 60,327 and 145,546 people with T2D respectively (55,728 and 76,593 oral medications). After adjustment in regression models metformin and SGLT2 inhibitors had the longest persistence, AGIs and meglitinides the shortest. TZDs, DPP4 inhibitors, and SGLT2 inhibitors had the highest adherence, and metformin, AGIs and meglitinides the lowest. Sulphonylureas had intermediate adherence and persistence. Younger age, female gender, and non-white ethnicity were also associated with reduced persistence and adherence. Adherence and persistence vary considerable between classes of medication for T2D. Class switching may improve adherence in people with low adherence e.g. metformin to DPP4 inhibitors. Pre-emptive selection of classes which promote adherence in those with non-adherence risk factors may also improve outcomes.
Supervisor: de Lusignan, Simon ; Whyte, Martin Sponsor: Eli Lilly
Qualification Name: Thesis (M.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.742091  DOI: Not available
Share: